MyoKardia has announced plans to issue more than nine million shares of its common stock priced at $13.3 a share, to raise $122.15m in gross proceeds.

Based in the US, MyoKardia is a biopharmaceutical company specialising in the development of therapies for cardiovascular diseases.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

US-based pharmaceutical company Kala Pharmaceuticals has announced an initial public offering of six million common stock shares priced between $14 and $16 a share, to raise a minimum of $84m and a maximum of $96m.

Kala plans to use the funds towards the clinical development of its KPI-121 drug and for other general corporate purposes.

Australian regenerative medicine company Mesoblast has announced plans for a public offering of American Depositary Shares (ADS) to raise up to $180m.

See Also:

"Australian regenerative medicine company Mesoblast has announced plans for a public offering of American Depositary Shares (ADS) to raise up to $180m."

Mesoblast plans to use the funds for general corporate purposes and to expand its business.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Evelo Biosciences has raised $50m through a Series B financing round that included participation from Flagship Pioneering, Google Ventures, Celgene, Mayo Clinic and Alexandria Venture Investments.

Based in the US, Evelo is a biotechnology company specialising in the development of cancer therapies. The funds will be utilised to advance the development of the company’s monoclonal microbial product candidates into clinical studies.

The product candidates are targeted at oncology and immuno-inflammatory diseases.